| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-718
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-305
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2004-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2007-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007505899-A |
| titleOfInvention |
Methods and compositions for preventing multi-organ dysfunction |
| abstract |
One aspect of the present invention is that within 24 hours of the occurrence of trauma, (i) a digestible water soluble carbohydrate and (ii) a liver guanosine-5′-triphosphate (GTP) increasing component and / or angiotensin converting enzyme ( The present invention relates to a method for preventing multiorgan dysfunction in a mammal having trauma, which comprises intestinal administration of a peptide having an ACE) inhibitory activity to a mammal. Another aspect of the invention is from 5 to 5000 mg in combination with -20 to 200 g / L dissolved digestible carbohydrate; and -1 to 100 g / L ribose equivalent and / or 2 to 2000 mg / L flavonoids. Relates to an aqueous liquid composition comprising: / L guanosine equivalent; or 0.01 to 10 mM peptide having ACE inhibitory activity; and 45 to 97.95 wt% water. |
| priorityDate |
2003-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |